Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

Glen J. Weiss, Raoul Tibes, Lisa Blaydorn, Gayle Jameson, Molly Downhour, Erica White, Ivor Caro, Daniel D. Von Hoff

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for blood, mammary, and neural development. We report on our experience of treating two patients with advanced BCC participating. These two patients have had no new BCCs develop for at least 2.25 years. Both patients have been receiving ongoing daily treatment with vismodegib for greater than 2.75 years without experiencing any significant side effects. After prolonged continuous daily dosing with a SMO antagonist, we have not observed a significant alteration in hematologic parameters or physical abnormalities of the pectoral regions of two patients with advanced BCC.

Original languageEnglish (US)
Article numbere55
JournalDermatology Reports
Volume3
Issue number3
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

HhAntag691
Basal Cell Nevus Syndrome
Basal Cell Carcinoma
Safety
Breast
Stem Cells
Clinical Trials
Genes
Neoplasms

Keywords

  • Basal cell carcinoma
  • Basal cell nevus syndrome
  • Hedgehog signaling pathway
  • Vismodegib

ASJC Scopus subject areas

  • Dermatology

Cite this

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome. / Weiss, Glen J.; Tibes, Raoul; Blaydorn, Lisa; Jameson, Gayle; Downhour, Molly; White, Erica; Caro, Ivor; Von Hoff, Daniel D.

In: Dermatology Reports, Vol. 3, No. 3, e55, 2011.

Research output: Contribution to journalArticle

Weiss, Glen J. ; Tibes, Raoul ; Blaydorn, Lisa ; Jameson, Gayle ; Downhour, Molly ; White, Erica ; Caro, Ivor ; Von Hoff, Daniel D. / Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome. In: Dermatology Reports. 2011 ; Vol. 3, No. 3.
@article{3bf1695cc9e14cceb1ad4b9bc7c6e5da,
title = "Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome",
abstract = "Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for blood, mammary, and neural development. We report on our experience of treating two patients with advanced BCC participating. These two patients have had no new BCCs develop for at least 2.25 years. Both patients have been receiving ongoing daily treatment with vismodegib for greater than 2.75 years without experiencing any significant side effects. After prolonged continuous daily dosing with a SMO antagonist, we have not observed a significant alteration in hematologic parameters or physical abnormalities of the pectoral regions of two patients with advanced BCC.",
keywords = "Basal cell carcinoma, Basal cell nevus syndrome, Hedgehog signaling pathway, Vismodegib",
author = "Weiss, {Glen J.} and Raoul Tibes and Lisa Blaydorn and Gayle Jameson and Molly Downhour and Erica White and Ivor Caro and {Von Hoff}, {Daniel D.}",
year = "2011",
doi = "10.4081/dr.2011.e55",
language = "English (US)",
volume = "3",
journal = "Dermatology Reports",
issn = "2036-7392",
publisher = "PagePress",
number = "3",

}

TY - JOUR

T1 - Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

AU - Weiss, Glen J.

AU - Tibes, Raoul

AU - Blaydorn, Lisa

AU - Jameson, Gayle

AU - Downhour, Molly

AU - White, Erica

AU - Caro, Ivor

AU - Von Hoff, Daniel D.

PY - 2011

Y1 - 2011

N2 - Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for blood, mammary, and neural development. We report on our experience of treating two patients with advanced BCC participating. These two patients have had no new BCCs develop for at least 2.25 years. Both patients have been receiving ongoing daily treatment with vismodegib for greater than 2.75 years without experiencing any significant side effects. After prolonged continuous daily dosing with a SMO antagonist, we have not observed a significant alteration in hematologic parameters or physical abnormalities of the pectoral regions of two patients with advanced BCC.

AB - Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for blood, mammary, and neural development. We report on our experience of treating two patients with advanced BCC participating. These two patients have had no new BCCs develop for at least 2.25 years. Both patients have been receiving ongoing daily treatment with vismodegib for greater than 2.75 years without experiencing any significant side effects. After prolonged continuous daily dosing with a SMO antagonist, we have not observed a significant alteration in hematologic parameters or physical abnormalities of the pectoral regions of two patients with advanced BCC.

KW - Basal cell carcinoma

KW - Basal cell nevus syndrome

KW - Hedgehog signaling pathway

KW - Vismodegib

UR - http://www.scopus.com/inward/record.url?scp=84859575423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859575423&partnerID=8YFLogxK

U2 - 10.4081/dr.2011.e55

DO - 10.4081/dr.2011.e55

M3 - Article

VL - 3

JO - Dermatology Reports

JF - Dermatology Reports

SN - 2036-7392

IS - 3

M1 - e55

ER -